CB2 Insights has launched the first in a series of monthly medical reports derived from real-world clinical treatments on a variety of healthcare conditions and modalities across the United States, Canada and United Kingdom.

CB2 Insights (CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules when looking to treat anxiety.  Sekar discusses how this trial will be carried out and what the data gained from it will be used for.

CB2 Insights Inc (CSE:CBII) (OTCQB:CBIIF) CEO Prad Sekar tells Proactive that the Ontario-based company is partnering with licensed producer FCM Global S.A.S.  Sekar says FCM Global is one of the only fully licensed Colombian cannabis producers where CB2 will support its medical cannabis research and clinical trials. Sekar is in New York presenting at the Piper Jaffray Healthcare Conference.

Pradyum Sekar, CEO of CB2 Insights (CSE:CBII), joined Anil Mall at Extraordinary Future 2019 in Vancouver to talk about CB2 Insights as a research and technology company with the aim of mainstreaming medical cannabis, hurdles they faced in the early days of the company, the three primary divisions of the company and their footprint in the US, their recent milestones and experience with going public earlier this year, and where Pradyum would like to see the space go in the next few years.

CB2 Insights (CNSX: CBII) CEO, Prad Sekar

CB2 Insights (CSE: CBII) (OTCQB: CBIIF) | SNN Network

CB2 Insights (CSE: CBII-OTCQB: CBIIT) CEO Prad Sekar joined Steve Darling on Skype from London with news the company has been selected as an exclusive research technology platform for the UK’s largest medical cannabis Pilot – Project TWENTY21  Sekar told Proactive about that project and how CB2 will be involved.

CB2 Insights (CSE: CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver to discuss the company moving into phase 2 of the integration of their program into the Juno platform.  Sekar tells Proactive about the results of phase 1 and what they were hearing from physicians using the system.

As a data aggregator within the medical cannabis space, CB2 Insights’ CEO Prad Sekar explains how the company is helping healthcare practitioners by providing more qualified data tools.

CB2 Insights (CSE: CBII)